LCG
CLDX icon

Lisanti Capital Growth’s Celldex Therapeutics CLDX Stock Holding History

Lisanti Capital Growth’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-1,198
Closed -$435K – 105
2013
Q4 		$435K Buy
+1,198
New +$462K 0.18% 105

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Lisanti Capital Growth's CLDX Position: Q1 2014 in Review

Lisanti Capital Growth sold out of Celldex Therapeutics (CLDX) in Q1 2014, closing a stake of 1,198 shares — an estimated $435K sold.

Lisanti Capital Growth first reported a position in CLDX in Q4 2013 and held it in 1 quarter. The position peaked at $435K in Q4 2013. 157 funds tracked by Wall St. Rank hold CLDX as of Q1 2014.

  • Lisanti Capital Growth reported no remaining Celldex Therapeutics position as of Q1 2014 after selling out during the quarter.
  • Lisanti Capital Growth sold 1,198 Celldex Therapeutics shares in Q1 2014, an estimated $435K.
  • Lisanti Capital Growth first reported a position in Celldex Therapeutics in Q4 2013 and held it in 1 quarter.
  • Lisanti Capital Growth's Celldex Therapeutics position peaked at $435K in Q4 2013.
  • 157 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2014.

Based on Lisanti Capital Growth's 13F filing for Q1 2014, filed 15 May 2014.